Palmetto
Veracyte Bladder Cancer Test Receives Medicare Coverage
The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies.
Palmetto Releases Draft LCD for Prostate Cancer Risk Stratification Tests
Under the local coverage determination, tests to help identify patients who may benefit from a prostate biopsy would be covered under certain conditions.
Bucking Downward 2021 Trend, 360Dx Index Rebounds 4 Percent in April
Of the 30 companies in the index, 18 firms saw their stock prices increase, while 12 saw their share prices decline.
Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection
Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status.
360Dx Index Jumps 31 Percent in 2020 as COVID-19 Shifts Attention to Dx Industry
Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double.Â